Publications by authors named "M P Ripault"
Article Synopsis
- The study investigates the prevalence and incidence of hepatitis E virus (HEV) infection in patients with inflammatory bowel disease (IBD) undergoing immunomodulatory treatment, given that these medications can compromise the immune system.
- Conducted across 16 French centers, the research involved 488 IBD patients, revealing very few cases of acute HEV infection, with a seroprevalence of 14.2% for chronic infection, particularly among older patients and those with higher seafood intake.
- The findings suggest that routine HEV screening isn't necessary for IBD patients on immunomodulators, but HEV should be tested if liver abnormalities occur.
Background: Alcohol-related cirrhosis is a frequent and difficult-to-treat disease. Despite the low hepatic metabolism of baclofen, data on its use in this subgroup are scarce. The French multicenter Observatory of patients treated with Baclofen for Alcohol DEpendence real-life cohort assessed: (a) prescription modalities of baclofen in liver units; (b) safety profile of baclofen; and (c) declared alcohol intake, biological markers of excessive alcohol intake and hepatic function at 12 months.
View Article and Find Full Text PDFPrognostic and risk factors for upper gastrointestinal bleeding (UGIB) might have changed overtime because of the increased use of direct oral anticoagulants and improved gastroenterological care. This study was undertaken to assess the outcomes of UGIB in light of these new determinants by establishing a new national, multicenter cohort 10 years after the first. Consecutive outpatients and inpatients with UGIB symptoms consulting at 46 French general hospitals were prospectively included between November 2017 and October 2018.
View Article and Find Full Text PDFIntroduction And Aim: Data on the efficacy and tolerance of interferon-free treatment in chronic hepatitis C (CHC) in elderly patients are limited in phase II-III trials.
Material And Methods: A prospective cohort of adult patients with CHC treated in French general hospitals.
Results: Data from 1,123 patients, distributed into four age groups, were analyzed.
Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH).
Presse Med
March 2019
Background And Aims: According to clinical trials, the treatment of patients with chronic hepatitis C (CHC) with second-generation direct acting antiviral agents (DAAs) is highly efficient and well tolerated. The goal of this study was to investigate the effectiveness and safety of various combinations of these drugs during their first 2 years of use in the real-world practice of French general hospitals.
Methods: Data from patients treated with all-oral DAAs in 24 French non-academic hospital centers from March 1, 2014 to January 1, 2016, were prospectively recorded.